Features
Get A Demo
Plans
Sign Up
Login
All Federal Contract IDV Awards
Help
Indefinite Delivery Contract HHSN261201200034I
Award Date
9/24/12
Last Date to Order
9/23/19
Overview
🤔 AI Insights
Buyer Personas
1
Industry Personas
Buyer Personas In this Market
2
Activity
Contract IDVs
Contract Awards
10
Transactions
7
Price Lists
Opportunity Stack
Federal Agency
National Cancer Institute
Awardee
The Univeristy Of Texas M.d. Anderson Cancer Center
Ultimate Awardee
Not listed
NAICS Category
541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
PSC Category
AN12 - Health R&D Services; Health Care Services; Applied Research
Federal Contract Vehicle
Cancer Prevention Agent Development Program 2012-2017
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Cancer Prevention Agent Development Program 2012-2017
Master IDIQ
HHSN261201200034I
Indefinite Delivery Contract
10
Federal Contract Awards
Description
Update #1
OTHER FUNCTIONS - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
Posted 9/21/12, 12:00 AM
Mod #
Description
Reason For Modification
Federal Obligation
(Click to sort descending)
Date
(Click to sort ascending)
P00006
OTHER FUNCTIONS - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
Other Administrative Action
$0
6/17/22
5
OTHER FUNCTIONS - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
Exercise an Option
$0
7/6/18
4
OTHER FUNCTIONS - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
Exercise an Option
$0
8/29/17
3
OTHER FUNCTIONS - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
Supplemental Agreement for work within scope
$0
1/18/17
2
OTHER FUNCTIONS - CANCER PREVENTION AGENT DEVELOPMENT PROGRAM: EARLY PHASE CLINICAL RESEARCH
Other Administrative Action
$0
10/30/15
Name
Description
Awardee
Potential Value
(Click to sort descending)
Award Date
(Click to sort descending)
Completion Date
(Click to sort descending)
Updated At
(Click to sort descending)
Delivery Order HHSN261201200034I-HHSN26100003
A PHASE IB BIOMARKER TRIAL OF NAPROXEN IN PATIENTS AT RISK FOR DNA MISMATCH REPAIR DEFICIENT COLORECTAL CANCER (MDA2013-01-02)
The Univeristy Of Texas M.d. Anderson Cancer Center
$1.3m
9/20/13
3/19/20
4/26/21
Delivery Order HHSN261201200034I-HHSN26100007
EFFECT OF ASPIRIN ON BIOMARKERS OF BARRETT'S ESOPHAGUS AFTER SUCCESSFUL ERADICATION OF BARRETT'S ESOPHAGUS WITH RADIOFREQUENCY ABLATION
The Univeristy Of Texas M.d. Anderson Cancer Center
$846.3k
6/15/15
5/31/21
8/30/21
Delivery Order HHSN261201200034I-75N91019F00129
The National Cancer Institute (NCI) awarded a $2,067,521.23 delivery order contract to the University of Texas MD Anderson Cancer Center (MD Anderson) to conduct early phase clinical research for the Cancer Prevention Agent Development Program. This contract is a child under the larger Cancer Prevention Agent Development Program 2012-2017 indefinite delivery vehicle. MD Anderson, as a comprehensive cancer research and treatment center, will provide various services in support of this cancer prevention initiative, including preclinical studies, clinical trials, and correlative analyses. The University of Texas System is the parent organization for MD Anderson. This contract does not have a set-aside designation.
The Univeristy Of Texas M.d. Anderson Cancer Center
$2.1m
9/10/19
9/22/24
6/27/24
Delivery Order HHSN261201200034I-HHSN26100012
This is a delivery order contract awarded by the National Cancer Institute (NCI) to The University of Texas MD Anderson Cancer Center (MD Anderson) valued at $658,199.33. The contract is for a phase I dose escalation study of a topical cancer prevention agent, bexarotene, in women at high risk for breast cancer. It is part of the NCI's Cancer Prevention Agent Development Program, an early-phase clinical research initiative. The contract does not have a set-aside designation. MD Anderson is a component of the University of Texas System, a large public university system that receives substantial federal funding for research and education programs across its institutions. Through prime and subcontract awards, MD Anderson has extensive experience conducting cancer-related research, including preclinical studies, epidemiologic investigations, and clinical trials, for various federal agencies.
The Univeristy Of Texas M.d. Anderson Cancer Center
$658.2k
9/1/17
4/30/22
12/13/24
Delivery Order HHSN261201200034I-HHSN26100011
This is a contract awarded by the National Cancer Institute (NCI), an institute within the National Institutes of Health (NIH), to The University of Texas MD Anderson Cancer Center. The $2,186,264.78 contract is for a randomized, double-blind, placebo-controlled study of a topical breast cancer prevention agent, 4-hydroxytamoxifen gel, in women with dense breast tissue. This contract was issued under the NCI's Cancer Prevention Agent Development Program, which supports early phase clinical trials of novel cancer prevention strategies. The University of Texas System, which includes MD Anderson, frequently receives prime and subcontract awards from federal agencies like NIH to support cancer research, treatment, and prevention initiatives across its institutions. This contract does not have a small business set-aside designation.
The Univeristy Of Texas M.d. Anderson Cancer Center
$2.2m
9/19/16
9/18/23
12/12/24